The Bellvitge Biomedical Research Institute (IDIBELL) states that Dr Manel Esteller, ICREA researcher, professor at the University of Barcelona, and until now, coordinator of the Epigenetics and Cancer Biology Program (PEBC) at IDIBELL, has been appointed director of the Josep Carreras Leukaemia Research Institute, a position that implies the termination of his employment relationship with IDIBELL.
Dr Esteller has led the PEBC since its creation in 2009. As an IDIBELL researcher and program coordinator, he has driven several research projects of excellence on cancer epigenetics and other diseases. Throughout these years, he has proven his talent, perseverance and productivity, qualities that translate into a broad recognition both scientifically and socially speaking.
IDIBELL has firmly and consistently supported the work carried out by Dr Esteller and the entire team of PEBC researchers, contributing to the development of their professional career and of the program. Now that the Institute is about to celebrate its 15th anniversary, we reaffirm our trust and support towards our researchers and their proven ability to generate knowledge focused on health outcomes. Due to its location and the daily healthcare activity that many of their researchers are carrying out, IDIBELL research groups can identify what issues constitute real priorities.
The Board of Trustees and the Directorate of IDIBELL wish Dr Esteller good luck and lots of success in his new venture as director of the Josep Carreras Leukaemia Research Institute. Both hope that the experience he gained at IDIBELL will help him face all upcoming challenges in the most appropriate way.
ABOUT IDIBELL
The Bellvitge Biomedical Research Institute (IDIBELL) is an internationally-renowned research center in biomedicine created in 2004. Its stakeholders are Bellvitge University Hospital and Viladecans Hospital of the Catalan Health Institute, the Catalan Institute of Oncology, the University of Barcelona and the City of L’Hospitalet de Llobregat. It currently has more than 1000 affiliated researchers working in the fields of cancer, neurosciences and translational and regenerative medicine.
In 2009, IDIBELL became one of the five first Spanish research centers certified as a health research institute by the Carlos III Health Institute. It is also a member of the CERCA institution of the Generalitat de Catalunya. Thanks to the support of the City Council of L’Hospitalet, IDIBELL will become a key element of the future biomedical microcluster planned for this area, located south of Barcelona.
More information
IDIBELL Communications & Scientific Culture Unit
932607825